Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus.

We report a case of radiation recall syndrome in a breast cancer patient, after introduction of everolimus. A woman with a right breast cancer underwent a mastectomy, then adjuvant chemotherapy, radiation therapy and hormonotherapy. In a phase III trial (UNIRAD protocol), she received everolimus 5 months after radiation therapy. Seven days after introduction, she was suffering from a radiation recall syndrome with exacerbation skin reactions. The exact pathophysiological mechanism of radiation recall syndrome is unknown. The combination of radiation therapy and mTor inhibitor, even sequentially, should be done with caution as several cases have already been reported. PMID: 31176579 [PubMed - as supplied by publisher]
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research

Related Links:

Conclusion: In patients who achieve ypN0 following NAC and mastectomy, PMRT shows no additional survival benefits for any molecular subtype. PMID: 31281730 [PubMed]
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
ConclusionThe preferred treatment is always aggressive surgical removal and, as our atypical clinical case suggests, neoadjuvant chemotherapy in very high doses is also needed. A biopsy of any suspicious breast skin lesion after radiotherapy is recommended. Despite the treatment challenges, our case provides enlightening details on the management of such a rare cancer even when faced with unplanned events which do not always allow for a textbook approach.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
ConclusionPRT/PCRT is associated with low grades of fibrosis and a  good to excellent long-term cosmetic outcome.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
This study evaluated the clinical significance of the lymph-node ratio (LNR) and its usefulness as an indicator of supraclavicular lymph-node radiation therapy (SCNRT) in pN1 breast cancer patients with disease-free survival (DFS) outcomes. We retrospectively analyzed the clinical data of patients with pN1 breast cancer who underwent partial mastectomy and taxane-based sequential adjuvant chemotherapy with postoperative radiation therapy in 12 hospitals (n = 1121). We compared their DFS according to LNR, with a cut-off value of 0.10. The median follow-up period was 66 months (range, 3–112). Treatment failed in 73...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conclusion: This study showed that the 21-gene RS assay was not able to predict the benefit of PMRT for OS in women with T1-2 N1mic ER-positive HER2-negative breast cancer. However, further prospective larger sample-size trials are warranted to determine if a benefit exists. Introduction According to the latest Global Cancer Statistics 2018, breast cancer is still the most frequent cancer and the leading cause of cancer death among females worldwide (1). It is estimated that there will be about 2.1 million newly diagnosed female breast cancer cases and 627,000 cancer death in 2018 (1). The use of screening tests for ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: This study is the first to demonstrate a dose-response relationship between risk of complications and near Dmax, where hypofractionated regimen or boost RT can play an important role. Rigorous RT-quality assurance program and modification of dose constraints could be considered as a critically important component for ongoing trials of hypofractionation. Based on our findings, we initiated a multi-center retrospective study (KROG 18-04) and a prospective study (NCT03523078) to validate our findings. Introduction Breast reconstruction provides important psychosocial, cosmetic, and quality of life benefits ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: IBR was associated with a modest increase in the duration from surgery to chemotherapy that was statistically but not clinically significant. Moreover, IBR had no influence on PMRT delay or survival outcomes, suggesting that it is an acceptable option for patients with non-metastatic breast cancer undergoing mastectomy. PMID: 30941238 [PubMed]
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
ConclusionLipofilling is a very useful tool that could help in cases of an uninfected exposed implant. It could also be used primarily as an adjunct procedure to implant based reconstruction to optimize the outcome.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
Carcinosarcoma is a rare, aggressive type of breast cancer accounting for
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
ConclusionsThe extent of surgery is not associated with improved survival in women with LBA, and patients may consider breast-conservation surgery. Adjuvant therapies are not associated with improved survival, with the exception of possible role of adjuvant chemotherapy in large primary tumors (5  cm or greater). Further clinical studies are needed to determine the impact of these treatments on local control, progression-free survival, and patients’ quality of life. Until then, the findings of our analysis will form basis for the multi-disciplinary discussion of management of women with L BA.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Mastectomy | Radiation Therapy | Science | Skin